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Abstract: Oxygen promotes closure of the ductus arteriosus at birth. We have previously presented a scheme for oxygen ac-
tion with a cytochrome P450 (CYP450) hemoprotein and endothelin-1 (ET-1) being, respectively, sensor and effector, and a
hypothetical monooxygenase product serving as a coupling link. We have also found in the vessel arachidonic acid (AA) 12
(S)-lipoxygenase (12-lipoxygenase) undergoing upregulation at birth. Here, we examined the feasibility of a sensor-to-effector
messenger originating from AA monooxygenase and 12-lipoxygenase pathways. The epoxygenase inhibitor, N-methylsulfonyl-
6-(2-)hexanamide, suppressed the tonic contraction of ductus to oxygen. A similar effect was obtained with 12-lipoxygenase
inhibitors baicalein and PD 146176. By contrast, none of the inhibitors modified the endothelin-1 contraction. Further-
more, an AA u-hydroxylation product, 20-hydroxyeicosatetraenoic acid (20-HETE), reportedly responsible for oxygen
contraction in the systemic microvasculature, had no such effect on the ductus. We conclude that AA epoxygenase and
12-lipoxygenase jointly produce a hitherto uncharacterized compound acting as oxygen messenger in the ductus.
Key words: ductus arteriosus, oxygen sensing, arachidonic acid epoxygenase, arachidonic acid lipoxygenase, arachidonic
acid u-hydroxylation, 20-hydroxyeicosatetraenoic acid, endothelin, fetal and neonatal physiology.
Résumé : L’oxygène favorise la fermeture du canal artériel à la naissance. Nous avons présenté antérieurement un méca-
nisme d’action de l’oxygène dans lequel une hémoprotéine, le cytochrome P450 (CYP450), et l’endothéline-1 (ET-1) sont
respectivement capteur et effecteur, et dans lequel un produit hypothétique de la monooxygénase agit comme agent de cou-
plage. Nous avons aussi noté une augmentation de l’arachidonate (AA) 12(S)-lipoxygénase (12-lipoxygenase) dans les vais-
seaux à la naissance. Dans la présente étude, nous avons examiné la possibilité qu’un messager capteur–effecteur émane des
voies de l’AA monooxygénase et de l’AA 12-lipoxygénase. L’inhibiteur de l’époxygénase, MS-PPOH, a supprimé la
contraction tonique du canal induite par l’oxygène. Un effet similaire a été obtenu avec les inhibiteurs de la 12-lipoxygénase,
baicaléine et PD 146176. Toutefois, aucun des inhibiteurs n’a modifié la contraction induite par l’ET-1. De plus, un produit
de l’u-hydroxylation de l’AA, l’acide 20-hydroxyéicosatétraénoïque (20-HETE), qui serait à l’origine de la contraction pro-
voquée par l’oxygène dans le système microvasculaire, n’a pas eu d’effet de ce genre sur le canal. Nous concluons que l’AA
époxygénase et l’AA 12-lipoxygénase coproduisent une substance, non caractérisée à ce jour, qui agit comme messager de
l’oxygène dans le canal.
Mots‐clés : canal artériel, capteur d’oxygène, acide arachidonique époxygénase, acide arachidonique lipoxygénase, u-hydroxylation
de l’acide arachidonique, acide 20- hydroxyéicosatétraénoïque, endothéline, physiologie fœtale et néonatale.
[Traduit par la Rédaction]
Introduction
The ductus arteriosus is a fetal shunt, connecting the pul-
monary artery with the aorta, that closes shortly after birth
coincidentally with the natural rise in blood oxygen tension.
Our previous studies have identified a cytochrome P450
(P450) hemoprotein of the 3A subfamily, specifically
CYP3A13 in the mouse, as the prime oxygen sensor within
ductal muscle and endothelin-1 (ET-1) as the ultimate effec-
tor for the contraction (Coceani 1999; Coceani et al. 1999;
Coceani and Kelsey 2000; Baragatti et al. 2011). Still unde-
fined, however, is the nature of the functional linkage be-
tween sensor and effector, although much evidence points to
a CYP450-based monooxygenase reaction as the source of
the putative messenger (Coceani et al. 1988; Coceani 1999).
Knowing the importance of the eicosanoid system in the con-
trol of blood vessels, the ductus included (Smith 1998), we
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have attempted in the past to link the oxygen contraction of
the ductus to an arachidonic acid (AA) epoxide (i.e., epoxyei-
cosatrienoic acid (EET)) but results have been negative (Co-
ceani et al. 1988). Lately, however, this system has acquired
a greater degree of complexity with the characterization of a
host of vasoactive agents, originating through epoxygenase-
and lipoxygenase-based reactions (Pace-Asciak et al. 1999;
Chen et al. 2008; Chawengsub et al. 2009), and the realiza-
tion of the potential for synthesis still being unfulfilled. Fur-
thermore, a product of AA u-hydroxylation, 20-
hydroxyeicosatetraenoic acid (20-HETE), has been implicated
in oxygen sensing of the systemic microvasculature (Kunert
et al. 2001).
Application of this new knowledge to the mechanism of
ductus closure has been limited or inconclusive. 20-HETE is
seemingly not found in the ductus despite the presence of an
appropriate CYP450 hemoprotein for its synthesis (Baragatti
et al. 2009). Conversely, there is an active 12-lipoxygenase
pathway, conceivably located in the muscle, whose function
needs to be determined (Baragatti et al. 2009). Significantly,
its initial enzyme, that is, 12/15-lipoxygenase (encoded by
Alox15)1, is markedly upregulated in the neonatal ductus
(Costa et al. 2006), as one would expect from any factor
linked to the process of closure.
From this premise, the objective of the present study in the
mouse ductus was twofold: (i) to assess the possible involve-
ment of AA epoxygenase and 12-lipoxygenase in the oxygen
activation sequence and (ii) to examine whether 20-HETE ac-
cords in its action with a role as oxygen mediator.
Materials and methods
Animals
Experiments were carried out with wild-type (WT)
C57BL/6 mice (Harlan, San Pietro al Natisone, Italy) (litter
size 1–12) and, in a few cases, with Cyp3a–/– mice of the
FVB strain (litter size 8–10) (courtesy of Dr. A.H. Schinkel;
see van Herwaarden et al. 2007). In a previous study, it has
been shown that the mutant lacks a critical isoform (i.e.,
CYP3A13) for oxygen sensing in the ductus (Baragatti et al.
2011). In addition, it has been confirmed that WT C57BL/6
and WT FVB strains share a similar response to oxygen in
their fetal duct (Baragatti et al. 2011). Animals were housed
in temperature- and humidity-controlled quarters, with con-
stant 12 h light : 12 h dark cycles, and were given food and
water ad libitum. Surgical procedures and experimental pro-
tocols were approved by the Animal Care Committee of the
Ministry of Health (Rome, Italy).
Solutions and drugs
The Krebs medium had the following composition: 118
mol/L NaCl, 4.7 mol/L KCl, 2.5 mol/L CaCl2, 1 mol/L
KH2PO4, 0.9 mol/L MgSO4, 11.1 mol/L dextrose, and 25
mol/L NaHCO3. Solutions were bubbled with gas mixtures
containing either no O2 or O2 in various concentrations
(2.5%, 12.5%, 30%, and 95%), plus 5% CO2 and balance N2,
with the intent of duplicating the fetal (2.5% O2) and neona-
tal (from 12.5% O2 upwards) conditions. For maximal con-
traction, oxygen is required at concentrations exceeding the
physiological range (Coceani et al. 1999), since a steep tissue
gradient may occur even with a small-size vessel (Fay 1973).
PO2 of the medium was measured with a Chiron gas analyzer
(model 248, Chiron Diagnostics,Halstead, UK) and was
0.84 ± 0.01 kPa (n = 41), 2.15 ± 0.01 kPa (n = 41), 6.33 ±
0.19 kPa (n = 21), 20.7 ± 0.2 kPa (n = 21), and 82.5 ± 0.1
kPa (n = 21) (pH 7.410 ± 0.005; n = 41) with 0%, 2.5%,
12.5%, 30%, and 95% O2 mixtures, respectively.
The following compounds were used: the suicide-substrate
inhibitor of AA epoxidation, N-methylsulfonyl-6-(2-)hexana-
mide (MS-PPOH, courtesy of Dr. M. Schwartzman) (Wang
et al. 1998); the 12-lipoxygenase inhibitor baicalein (Sigma–
Aldrich, St. Louis, Mo., USA), with a confirmed selective ac-
tion in the ductus arteriosus (Baragatti et al. 2009); the 12/
15-lipoxygenase inhibitor, 6,11-dihydro-5-thia-11-aza-benzo
[a]-fluorene (PD 146176) (Sendobry et al. 1997; DeCostanzo
et al. 2010); 20-HETE (Cayman Chemical, Ann Arbor,
Mich., USA); the thromboxane A2 (TXA2) analog 9,11-epi-
thio-11,12-methano-TXA2 (ONO-11113; courtesy of ONO
Pharmaceutical, Osaka, Japan); the prostaglandin (PG) endo-
peroxide analog and TXA2 mimic 9a,11a-epoxy-methano-15-
hydroxy-prosta-5,13-dienoic acid (U-44069; Cayman Chemi-
cal); and endothelin-1 (ET-1; human–porcine type; Peninsula
Laboratories, San Carlos, Calif., USA). Concentrations of the
inhibitors were derived from the literature with the aim of
combining efficacy with selectivity.
ONO-11113 and U-44069 were dissolved in distilled ethanol
(respectively 5 and 0.1 mg/mL), and aliquots (stored at –70 °C)
were diluted, respectively, with Tris buffer (pH 7.4) and sal-
ine. MS-PPOH, baicalein, and PD 146176 were also dis-
solved in ethanol (respectively 16.15, 1.35, and 2.37 mg/mL)
before the final solution was prepared in Krebs medium.
20-HETE was first dissolved in ethanol (0.1 mg/mL), and
then an appropriate aliquot was evaporated to near dryness
under a stream of N2 before being reacted with a stoichio-
metric amount of Na2CO3; the resulting product was pre-
pared as a 100 µmol/L stock in Tris buffer (pH 9.0) to be
ultimately diluted with Krebs medium as required. ET-1
was dissolved in sterile water with 0.05% human serum al-
bumin (100 µmol/L), and aliquots of this stock solution
were stored at –20 °C until use. Ethanol concentration in
fluid bathing the ductus preparations did not exceed 0.01%
(MS-PPOH), 0.2% (baicalein), 0.01% (PD 146176), 0.001%
(ONO-11113), or 0.1% (U-44069). Ethanol vehicle has no
significant effect at the given concentrations (Reese et al.
2009), and this was confirmed here. Solutions of baicalein
were protected from light.
Concentrations of compounds are given in molar units and
refer to their final value in Krebs medium.
In vitro recording
Term fetal mice, both WT and Cyp3a–/– (gestational age
19 days), were delivered by cesarean section under halothane
anesthesia and were killed by cervical dislocation. Body
weight was 0.8–1.5 and 1.0–1.3 g, respectively, for WT and
mutant, and only 1 fetus was used in each experiment. Proce-
dures for ductus dissection, normalization of internal circum-
ference, and mechanical record have been described (Coceani
et al. 1999). Briefly, the animal was secured with its left side
112/15-lipoxygenase manifests predominantly 12-lipoxygenase activity in rodents (Johannesson et al. 2010).
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up in a dissection chamber containing ice-cold Krebs solution
gassed with 5% CO2 in N2. Through thoracotomy, the ductus
was exposed, separated from adjoining blood vessels, and
suspended onto 25 µm tungsten wires (Cooner Wire Com-
pany, Chatsworth, N.J., USA) inside an organ bath. Fluid
was gassed with a mixture containing 2.5% O2, and the same
gas mixture was flushed through a hood covering the bath.
Preparations were then equilibrated (about 60 min at 37 °C)
under minimal stretch (WT: 0.046 ± 0.001 mN/mm; n = 38)
(Cyp3a–/–: 0.048 ± 0.001 mN/mm; n = 3), and the attendant
internal circumference (C0) with related resting dimension
(WT: vessel length, long side: 567 ± 13 µm; vessel length,
short side: 554 ± 13 µm; internal diameter: 134 ± 1 µm;
wall thickness: 20 ± 0.3 µm; n = 38) (Cyp3a–/–: vessel
length, long side: 533 ± 18 µm; vessel length, short side:
518 ± 15 µm; internal diameter: 134 ± 2 µm; wall thickness:
19 ± 1 µm; n = 3) served as a reference for choosing the ap-
propriate load. Afterwards, tension was applied to attain an
operating circumference (i.e., C50) coinciding with the condi-
tion in vivo (WT: 0.460 ± 0.005 mN/mm; n = 38)
(Cyp3a–/–: 0.460 ± 0.009 mN/mm; n = 3). The actual ex-
periment was started after a second equilibration of 60–
120 min.
The study comprised 2 groups of experiments dealing, re-
spectively, with the action of inhibitors of AA epoxygenase
and 12-lipoxygenase on oxygen-induced contraction and with
the response of the ductus to 20-HETE. In group 1 (n = 35),
oxygen action was examined over a range of concentrations
(12.5%, 30%, 95%) in the absence and presence of MS-
PPOH (5 µmol/L), baicalein (10 µmol/L), or PD 146176
(1 µmol/L). Inhibitors were tested comparatively on the duc-
tus contraction with ET-1 in view of the role being assigned
to this compound as the ultimate effector in the oxygen
activation sequence (Coceani 1999; Coceani et al. 1999;
Fig. 1. Differential effect of arachidonic acid epoxygenase and 12-lipoxygenase inhibitors on the oxygen- versus ET-1-induced contraction in
the isolated mouse ductus arteriosus. (a, c) Concentration–response curves to oxygen before (open circle; n = 6) and during treatment with (a)
MS-PPOH (5 µmol/L) (closed circle; n = 4) and (c) baicalein (10 µmol/L) (closed circle; n = 4) or PD 146176 (1 µmol/L) (half-filled circle;
n = 4). (b, d) Concentration–response curves to ET-1 before (open circle; n = 6) and during treatment with (b) MS-PPOH (5 µmol/L) (closed
circle; n = 4) and (d) baicalein (10 µmol/L) (closed circle; n = 4). *, p < 0.01 relative to control. Note that control curves for oxygen and ET-
1 were obtained concomitantly with another study (Baragatti et al. 2011) and are presented here again with one more experiment added to
each group. In this and the following figure, certain values are defined by one- rather than two-way error bars for better clarity. ET-1,
endothelin-1; MS-PPOH, N-methylsulfonyl-6-(2-)hexanamide.
Fig. 2. Effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on the
isolated mouse ductus arteriosus. Concentration–response curve in
wild-type (WT; open circle) and Cyp3a–/– mutant (closed circle)
(n = 3 for both groups).
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Baragatti et al. 2011). ET-1 was applied to the organ bath
in cumulative concentrations (0.1–300 nmol/L), using 3- to
10-fold increments. In group 2 (n = 6), 20-HETE action was
studied comparatively in WT and Cyp3a–/– preparations, expect-
ing that for the sake of compensation a messenger function
of the compound may be magnified in the mutant. 20-HETE was
tested cumulatively in 10-fold increments (1 pmol/L–1 µmol/L).
In either protocol, ONO-11113 (0.1 µmol/L) and, in some
experiments, U-44069 (0.3 µmol/L) provided a reference
for maximal contraction. For analysis of responses, baseline
was taken as the net tension (i.e., total tension minus ap-
plied tension) developed by the preparation before any treat-
ment. Any response to tests was measured by the change in
tension relative to baseline and was expressed in absolute
values.
Statistical analysis
Data are presented as means ± SE. Comparisons were
made using Student’s t tests or two-way ANOVA followed
by the Bonferroni test (SPSS program for Windows 10;
SPSS, Inc., Chicago, Ill., USA). Differences were considered
significant at p < 0.05.
Results
As previously reported (Baragatti et al. 2011), the WT
ductus developed a variable degree of tension during equilibra-
tion at 2.5% O2 (0.067 ± 0.018 mN/mm, n = 38) and, once
stabilized, contracted to oxygen in a concentration-dependent
manner (Figs. 1a, 1c). ET-1 was also a constrictor from
about 0.1 to 30 nmol/L, but the response in part subsided
beyond that range (Figs. 1b, 1d). Transient contractions of
uneven amplitude (0.1–0.7 mN/mm) and (or) low-amplitude
discharges were often superimposed on the baseline and
tended to increase during exposure to either agent. Unlike
WT, the Cyp3a–/– ductus developed little or no tone at rest
(see Baragatti et al. 2011), but its baseline still presented
fast activity in 2 of 3 experiments. All preparations,
whether WT or Cyp3a–/–, contracted to reference spasmo-
gens ONO-11113 (0.1 µmol/L; WT: 1.08 ± 0.07 mN/mm;
n = 12) and U-44069 (0.3 µmol/L; WT: 0.86 ± 0.09;
Cyp3a–/–: 1.00 ± 0.04 mN/mm; n = 3 for both).
The AA epoxygenase inhibitor MS-PPOH (5 µmol/L) had
no effect on basal tension, but completely inhibited the tonic
contraction to oxygen over its entire range of concentrations
(Fig. 1a). In fact, the contraction was replaced by a relaxation
in 2 experiments and, moreover, in one of them the response
was concentration dependent. However, transient changes in
tension, whether slow or fast in character, persisted through-
out treatment. Contrary to its effect on oxygen, MS-PPOH
did not alter the contractile response to either ET-1 (Fig. 1b)
or ONO-11113 (1.01 ± 0.08 mN/mm; n = 7).
The AA 12-lipoxygenase inhibitors baicalein (10 µmol/L)
and PD 146176 (1 µmol/L) contracted the resting ductus in
all cases (baicalein: 0.43 ± 0.07 mN/mm, n = 8; PD
146176: 0.31 ± 0.05 mN/mm, n = 4). No further increase in
tone occurred in baicalein-treated preparations upon exposure
to oxygen but, on the contrary, the original contraction was
replaced by a concentration-dependent relaxation (Fig. 1c).
Also curtailed was the oxygen response during treatment
with PD 146176, although to a lesser degree compared with
the response to baicalein (Fig. 1c). Conversely, ET-1 action
was not affected by baicalein, the modest shift rightward of
the concentration–response curve being insignificant (Fig. 1d).
Likewise, ONO-11113 elicited a full-fledged contraction in
the presence of either inhibitor (baicalein: 1.02 ± 0.05 mN/
mm, n = 8; PD 146176: 0.85 ± 0.19 mN/mm, n = 4).
At variance with findings in the systemic circulation (Ku-
nert et al. 2001), 20-HETE did not contract the ductus but
instead produced a modest relaxation (Fig. 2). No difference
in the pattern of the response was noted between WT and
Cyp3a–/– preparations (Fig. 2).
Discussion
Our study accords with the concept of a CYP450 hemo-
protein serving as sensor in the ductus constriction to oxygen
and, moreover, links its operation with an AA-based epoxy-
genase reaction. Critical to our conclusion is the outcome of
tests with MS-PPOH. In fact, by curtailing the tonic but not
the phasic component of the oxygen response, this inhibitor
mimicked in full the behaviour of the ductus lacking the sen-
sor hemoprotein (i.e., CYP3A13; see Baragatti et al. 2011).
Furthermore, considering the specificity of MS-PPOH as AA
epoxygenase inhibitor (Wang et al. 1998), the same data
argue against any involvement of a CYP450-based, AA u-
hydroxylation reaction. This assumption is also strengthened
by the negative results with 20-HETE, which according to
current knowledge would be the prime candidate as oxygen
mediator among the hydroxylation products (Kunert et al.
Fig. 3. Proposed scheme for arachidonic acid metabolism in the ductus arteriosus. Prostaglandin E2 is known to sustain prenatal patency,
whereas a hitherto unidentified product from the combined action of 12(S)-lipoxygenase and epoxygenase is assigned a messenger role in the
oxygen-induced postnatal closure.
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2001). Quite unexpectedly, it was also found that the oxygen
response is curtailed by treatment with a 12-lipoxygenase in-
hibitor. This finding, while providing a possible meaning to
the marked upregulation of this enzyme in the neonatal duc-
tus (Costa et al. 2006), raises the prospect of the putative
oxygen messenger originating from the combined activity of
AA epoxygenase and 12-lipoxygenase pathways. Our discus-
sion will address this possibility.
Among AA lipoxygenases, 12-lipoxygenase is in principle
well suited to a messenger role. Several data, for example,
implicate this pathway in synaptic function (DeCostanzo et
al. 2010). In addition, the initial metabolite (i.e., hydroperoxy
product) in this and the allied 15-lipoxygenase pathways
yields diverse active products (Pace-Asciak et al. 1999; Cha-
wengsub et al. 2009). Significantly, this transformation may
require the presence of a CYP450 hemoprotein, operating
though as a hydroperoxide isomerase rather than an epoxyge-
nase (Chawengsub et al. 2009). Hence, given the great poten-
tial of the eicosanoid system, it is not too far-fetched to think
that the putative oxygen messenger may derive from the con-
certed operation of 2 distinct AA pathways. But what is the
actual evidence in support of this concept? So far, 2 facts
may be brought to bear. It has been shown that 12-HETE,
with either “R” or “S” configuration, may serve as a substrate
for epoxygenase (Jajoo et al. 1992; J.R. Falck, personal com-
munication). Furthermore, CYP3A hemoproteins, which are
not regarded as prime catalytic elements for fatty acid epoxi-
dation, are still able to function as an AA epoxygenase (Aya-
jiki et al. 2003). Future work will build on this information
while attempting to characterize the hypothetical messenger.
In the meantime, it should be pointed out that a positive out-
come from this search would reassert the central position of
the eicosanoid system in ductus regulation, with the relaxant
PGE2 prevailing prenatally and an epoxygenase–lipoxygenase
product taking over postnatally (Fig. 3).
A final point deserves a comment relating to the nature of
the contractile effect of baicalein and PD 146176 on the duc-
tus. An unspecific phenomenon, being related to the known
antioxidant action of baicalein, can be ruled out, since this
particular property is not shared by PD 146176 (Sendobry et
al. 1997). More likely, the response results from some inter-
ference with PGE2 function, which both inhibitors have in
common (Sendobry et al. 1997; Woo et al. 2006).
In conclusion, our study marks a significant step forward in
the knowledge of oxygen sensing in the ductus. The identity
of the postulated CYP3A13 (sensor) to ET-1 (effector) mes-
senger remains undefined. However, valuable information has
been obtained on its possible mechanism of synthesis that
should provide guidance towards the ultimate characterization.
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